{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:14:20Z","timestamp":1777652060024,"version":"3.51.4"},"reference-count":13,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.25-0389","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T22:11:32Z","timestamp":1760479892000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["A Case of Occult Breast Cancer Diagnosed during Immune Checkpoint Inhibitor Treatment for Recurrent Metastatic Lung Cancer"],"prefix":"10.70352","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6610-903X","authenticated-orcid":false,"given":"Mio","family":"Makino","sequence":"first","affiliation":[{"name":"Department of Breast Surgical Oncology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-7989","authenticated-orcid":false,"given":"Hiroki","family":"Kusama","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-9947","authenticated-orcid":false,"given":"Masaru","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":false,"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology (Medical Research Center), Institute of Medical Science, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-4533","authenticated-orcid":false,"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Hessler LK, Molitoris JK, Rosenblatt PY, et al. Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the National Cancer Database. Ann Surg Oncol 2017; 24: 2907\u201314.","DOI":"10.1245\/s10434-017-5928-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Terada M, Adachi Y, Sawaki M, et al. Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes. Breast Cancer Res Treat 2018; 172: 1\u20137.","DOI":"10.1007\/s10549-018-4898-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Herbst RS, Giaccone G, De Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 2020; 383: 1328\u201339.","DOI":"10.1056\/NEJMoa1917346"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823\u201333.","DOI":"10.1056\/NEJMoa1606774"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol 2023; 41: 1200\u201312.","DOI":"10.1200\/JCO.22.01503"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019; 20: 1395\u2013408.","DOI":"10.1016\/S1470-2045(19)30407-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Masui Y, Shukuya T, Kataoka S, et al. Second malignancy in advanced or recurrent non-small cell lung cancer after the advent of molecular targeted drugs and immunotherapy. Thorac Cancer 2024; 15: 2291\u20137.","DOI":"10.1111\/1759-7714.15457"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Lv F, Cheng M, Jiang L, et al. Survival analysis of patients with primary breast duct carcinoma and lung adenocarcinoma: a population-based study from SEER. Sci Rep 2021; 11: 14790.","DOI":"10.1038\/s41598-021-94357-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415\u201321.","DOI":"10.1038\/nature12477"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 2019; 5: 74\u201382.","DOI":"10.1001\/jamaoncol.2018.4224"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379: 2108\u201321.","DOI":"10.1056\/NEJMoa1809615"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396: 1817\u201328.","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168: 707\u201323.","DOI":"10.1016\/j.cell.2017.01.017"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0389\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:33:14Z","timestamp":1760761994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0389\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0389","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.25-0389"}}